Shares of Axovant, Alzheimer’s Drug Developer, Surge on Trading Debut
The company, which bought an unproven Alzheimer’s drug for $ 5 million, is now valued at nearly $ 3 billion. The successful debut renews concerns that biotechnology stocks are in bubble territory.